VKTX vs. NVDA

In the year-to-date period, VKTX achieves a -33.40% return, which is significantly lower than NVDA's 0.63% return. Over the past 10 years, VKTX has underperformed NVDA with an annualized return of 13.09%, while NVDA has yielded a comparatively higher 74.01% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Viking Therapeutics, Inc. (VKTX) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current VKTX Sharpe Ratio is -0.68, which is lower than the NVDA Sharpe Ratio of 0.38. The chart below compares the historical Sharpe Ratios of VKTX and NVDA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

VKTX has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.02%.

The maximum VKTX drawdown since its inception was -90.41%, roughly equal to the maximum NVDA drawdown of -89.73%. Use the drawdown chart below to compare losses from any high point for VKTX and NVDA.

Viking Therapeutics, Inc. (VKTX) has a higher volatility of 16.04% compared to NVIDIA Corporation (NVDA) at 10.81%. This indicates that VKTX's price experiences larger fluctuations and is considered to be riskier than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Viking Therapeutics, Inc. and NVIDIA Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.